Posted Jun. 18, 2013 at 7:56 p.m.

Premium Lock Dara licenses diabetes compound to new RTP firm with CNS focus

Published: 2013-06-18 19:56:18
Updated: 2013-06-18 19:56:18

Print this blog post

Dara BioSciences spent years developing DB959 for diabetes. Now it's been licensed to T3D Therapeutics, which plans to study it in Alzheimer's disease. Read why T3D is a good fit for DB959's new focus....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners


Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Vivek Wadhwa